Meeting
2013 ASCO Annual Meeting
Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer.
Authors
Yasuhiro Funahashi
Eisai Inc., Andover, MA
Yasuhiro Funahashi , Richard T. Penson , Matthew A. Powell , David S. Miller , Jean Fan , Min Ren , Nicole Meneses , Pallavi Sachdev , Tadashi Kadowaki , James P. O'Brien , Ignace Vergote
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01111461
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5591)
DOI
10.1200/jco.2013.31.15_suppl.5591
Abstract #
5591
Poster Bd #
52B
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.
First Author: Pallavi Sachdev
Poster
2013 ASCO Annual Meeting
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes.
First Author: Ignace Vergote
Poster
2019 ASCO Annual Meeting
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
First Author: Vicky Makker
Poster
2023 ASCO Annual Meeting
The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).
First Author: Daniel D. Buchanan